Methods for determining carrier status
The invention generally relates to methods for determining carrier status with respect to a condition or disease. In certain embodiments, the method involves exposing a sample to a plurality of molecular inversion probes capable of capturing DNA from at least one genomic region suspected of having an altered copy number and at least one internal control DNA known or suspected to have a stable copy number, capturing and sequencing DNA that binds to the molecular inversion probes, and determining a copy number state of the at least one genomic region based on the sequence results.
1. A method for determination of copy number, the method comprising the steps of:
exposing a sample to a plurality of molecular inversion probes (MIPs), wherein a first MIP hybridizes to a genomic region suspected of having an altered copy number and a second MIP hybridizes to an internal control DNA suspected of having a stable copy number;
capturing, using the MIPs, the genomic region and the internal control DNA in said sample;
sequencing said genomic region and the internal control DNA, thereby to obtain sequence reads;
operating a computer system to
provide read counts, of the sequence reads, for said genomic region and the internal control DNA;
normalize said read counts for the genomic region with respect to the internal control DNA;
compare normalized read counts for said genomic region with a standard; and
infer copy number status of said genomic region based upon said comparing step.
2. The method of claim 1 , wherein said genomic region is implicated in an autosomal recessive disorder.
3. The method of claim 2 , wherein said genomic region is SMN1 or SMN2.
4. A method for determination of copy number, the method comprising the steps of:
exposing a sample to a plurality of molecular inversion probes (MIPs) that include a first MIP capable of hybridizing to a locus in DNA from the sample and a second MIP capable of hybridizing to a control locus in the DNA;
capturing, with said plurality of probes, the locus and the control locus;
sequencing said the captured locus and the control locus to obtain sequence reads;
analyzing, by a computer system, the sequence reads to obtain read counts for the locus and the control locus;
normalizing said read counts for the locus with respect to the control locus, the copy number of which is stable;
comparing normalized read counts for the locus with a standard; and
inferring copy number status of the locus based upon said comparing step.
5. The method of claim 1 , wherein the computer system comprises a processor couple to a memory.
6. The method of claim 1 , wherein the step of exposing a sample comprises obtaining a sample from a patient, the sample comprising genomic DNA that includes a genomic region suspected of having an altered copy number; and fragmenting the genomic DNA to yield target nucleic acid comprising fragments of the genomic region.
7. The method of claim 6 , further comprising the step of diagnosing a carrier phenotype for spinal muscular atrophy.
8. The method of claim 1 , wherein the sequencing step comprises a next-generation sequencing method.
9. The method of claim 1 , further comprising determining a difference between the copy number status of the genomic region and a copy number distribution encompassing a plurality of stable control loci.
10. The method of claim 1 , wherein the sample is blood.
11. The method of claim 4 , wherein the computer system comprises a processor couple to a memory.
12. The method of claim 4 , wherein the step of exposing a sample comprises obtaining a sample from a patient, the sample comprising genomic DNA that includes a genomic region suspected of having an altered copy number; and fragmenting the genomic DNA to yield target nucleic acid comprising fragments of the genomic region.
13. The method of claim 12 , wherein the genomic region comprises a first gene and a second gene, wherein the first and second genes are homologs, orthologs, or paralogs.
14. The method of claim 12 , further comprising the step of diagnosing a carrier phenotype for spinal muscular atrophy.
15. The method of claim 4 , wherein the sequencing step comprises a next-generation sequencing method.
16. The method of claim 4 , further comprising determining a difference between the copy number status of the locus and a copy number distribution encompassing a plurality of stable control loci.
17. The method of claim 4 , wherein the sample is blood.